NCT04859426View on ClinicalTrials.gov

A Study to Evaluate the Pharmacokinetics and Safety of DBPR108 in Subjects With Hepatic Impairment

PHASE1CompletedINTERVENTIONAL

Enrollment

24

Participants

Timeline

Start Date

June 9, 2021

Primary Completion Date

May 14, 2022

Study Completion Date

May 17, 2022

Conditions

Hepatic Impairment

Interventions

DRUG

DBPR108 tablets

Drug: DBPR108, tablet, oral

Trial Locations (1)

Unknown

First Affiliated Hospital of Soochow University, Suzhou

All Listed Sponsors

lead

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

INDUSTRY